Why BI Bid Farewell To Biosimilars
Executive Summary
The German group pharma's chief told Scrip "innovation drives the business" and confirmed that biosimilars have been abandoned apart from its Humira version Cyltezo in the US.
| Table |
|---|
Advertisement
Related Content
Topics
- Subjects
- Biosimilars
- Companies
- Strategy
- Research & Development
- Therapy Areas
- Cancer
- Immune Disorders
- Industries
- BioPharmaceutical
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125188
Ask The Analyst
Please Note: Click here for more information on the Ask the Analyst service.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC125188
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.